Brazil Forges Path to Affordable Cancer Therapy with New International Partnership

SÃO PAULO, BRAZIL – April 10, 2026 – Brazil is taking a significant step toward democratizing access to one of the world's most advanced cancer treatments. A new technology licensing agreement between Chinese biopharmaceutical firm IASO Biotechnology and Brazil's esteemed Instituto Butantan aims to bring revolutionary CAR-T cell therapy to the nation's public health system, potentially slashing a treatment cost that can soar to half a million dollars per patient.

The partnership, announced today, will enable the local development and manufacturing of a CAR-T therapy for hematological cancers. This cutting-edge treatment, which engineers a patient's own immune cells to fight their cancer, has offered new hope for individuals who have exhausted conventional options like chemotherapy and radiation. However, its prohibitive cost has kept it out of reach for the vast majority of Brazilians who rely on the Unified Health System (SUS).

By localizing production within a public institution, the collaboration seeks to dismantle the financial barriers that have relegated this life-saving therapy to the private sector. The cells will be developed and manufactured at the Advanced Therapies Center of São Paulo (Nutera-SP), a specialized facility coordinated by Butantan, leveraging the institute's deep-rooted expertise in immunobiologicals to pioneer access to next-generation medicine.

A New Model for Access

This agreement represents a pivotal strategic move for both parties. For IASO Bio, it marks a significant entry into the Latin American market. For Butantan, it's a major expansion of its public health mission beyond its traditional role as a leading producer of vaccines and serums.

"This partnership with Butantan is a pivotal milestone in IASO Bio's global strategy to bring our innovative cell therapies to patients in Latin America," said Jinhua Zhang, Founder, Chairwoman and CEO of IASO Bio. Zhang emphasized that combining IASO Bio's technology with Butantan's public manufacturing capabilities creates a "unique opportunity to significantly reduce costs and make this life-saving treatment accessible to many more patients in Brazil through the public health system."

The sentiment is echoed by Butantan's leadership, who view the deal as a crucial step toward fulfilling the institute's mandate.

"This treatment revolutionized the fight against hematological diseases, but access to it remains a challenge," stated Esper Kallás, Director of the Butantan Institute. "The new partnership allows the Butantan Institute, as a public institution, to expand its portfolio of advanced therapies to meet the needs of Brazilian public health, expanding access to cutting-edge technologies."

The High Cost of Hope

The need for such an initiative is stark. In Brazil, CAR-T therapy has been a tale of two healthcare systems. Since 2019, only an estimated 120 individuals have received the treatment, almost exclusively within the private system. The cost, which can reach US$500,000 (R$2.6 million), makes it an impossibility for the millions dependent on public care.

Brazil's Health Regulatory Agency, ANVISA, officially opened the door to this technology in February 2022 with the approval of the first commercial CAR-T product, tisagenlecleucel (Kymriah). While a regulatory milestone, the approval did little to solve the fundamental problem of affordability. The therapy remained a luxury, unavailable through the SUS.

This access crisis has spurred a broader national strategy to domesticate CAR-T production. The IASO Bio-Butantan partnership is a key part of a larger trend, joining other significant initiatives, such as a collaboration between Brazil's Ministry of Health, the nonprofit Caring Cross, and the Oswaldo Cruz Foundation (Fiocruz). These efforts share a common goal: to leverage local production to dramatically lower the price point and integrate CAR-T into the public system.

The Economics of Local Production

The core of the strategy lies in simple economics: moving production from foreign commercial labs to domestic public institutions. The financial implications are transformative. While the IASO-Butantan agreement did not specify a final price, other local initiatives provide a compelling benchmark. The Fiocruz/Caring Cross project, for example, aims to produce CAR-T doses for approximately $35,000—a staggering 90% reduction from the peak commercial price.

Researchers involved in Brazil's homegrown CAR-T development efforts have estimated that local manufacturing can be achieved at approximately one-third the cost of imported commercial products. For a healthcare system that spends tens of millions of dollars annually on less effective third-line cancer treatments, the long-term savings could be immense, even after accounting for the substantial upfront investment in facilities and clinical trials.

By bringing production in-house, Brazil aims to create a sustainable model where CAR-T therapy is no longer a budget-breaking anomaly but a standard, accessible option for eligible patients. This would not only improve patient outcomes but also position Brazil as a regional leader in making advanced cell and gene therapies a public health reality.

From Lab to Bedside: The Road Ahead

While the agreement marks a significant breakthrough, the path from licensing deal to widespread patient access is complex. Successfully integrating a highly personalized and logistically demanding therapy into the vast infrastructure of the SUS presents considerable challenges that extend beyond cost.

Manufacturing CAR-T cells requires sophisticated cleanroom facilities and highly trained personnel. While facilities like Nutera-SP provide a starting point, scaling production to meet national demand will require significant investment in both infrastructure and workforce development. A new generation of hematologists, oncologists, nurses, and lab technicians will need specialized training to handle everything from cell collection (apheresis) to managing the potentially severe side effects of the treatment.

Furthermore, clear regulatory and referral pathways must be established. ANVISA has an accelerated evaluation pathway for advanced therapies, but clinical trials must be successfully completed. The Carthedrall Clinical Study, another Brazilian CAR-T initiative, provides a potential timeline, with researchers hoping to apply for regulatory registration in the second half of 2026, contingent on trial recruitment.

Despite the hurdles, the commitment from Brazil's leading public health institutions is unwavering. For scientists on the front lines, this is more than a manufacturing agreement; it is a turning point for the nation's scientific and medical capabilities.

As Vanderson Rocha, coordinator of Nutera-SP and a Full Professor of Hematology, noted, the local development of CAR-T by a public institution is a "milestone for Brazilian science." He added that in the future, "the therapy could expand treatment possibilities for patients who no longer respond to conventional therapies."